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ABSTRACT 
 
INTRODUCTION:  
To study tolerogenic immunological mechanisms we use lentiviral based gene therapy in 
collagen-induced arthritis. In our tolerogenic model, collagen type II expression is enhanced 
on MHC class II on all types of antigen-presenting cells. After this treatment only 5% of mice 
develop arthritis at the same time as >95 % of control mice do. This study’s focus is before 
immunisation and days 3 and 5 after. 
METHOD: 
 Gene expression analysis in draining lymph nodes was performed using an immune card 
array, where the mRNA expression of 96 inflammation related genes was determined by 
quantitative PCR. Differences in relative quantification was investigated using multivariate 
analyses OPLS-DA and PLS. The presence of regulatory T cells in spleen and draining lymph 
nodes was determined by CD4 and Foxp3 expression using flow cytometry. 
RESULTS:  
At day 3 mRNA expression of both Socs1 and Il10 was positively while Ifng and Il6 was 
negatively associated to tolerance. At the same time the frequency of CD4+FoxP3+ cells 
where significantly increased in tolerant mice. 
CONCLUSIONS:  
In tolerant mice, overexpression of collagen type II on MHC II leads to upregulation of 
SOCS1 at day 3 after CIA induction. SOCS1 inhibits the JAK/STAT pathway. 
Simultaneously, we see down-regulation of pro-inflammatory cytokines such as IFN-g and 
IL-6 as well as to increased levels of immunoregulatory IL-10. These findings coincide with 
an expansion of regulatory T cells. Thus, the arthritogenic immune response is switched of 
during an early stage of CIA and aborts arthritis develoment. 
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INTRODUCTION  
 
The immune system of a healthy individual is tolerant towards the constituents of its host’s 
tissues. Though protected through a multitude of failsafe mechanisms this tolerance can be 
breached and autoimmune disease be developed. Autoimmune disease is characterised by an 
immune response towards self-antigens. 
Rheumatoid arthrithis (RA) the most common rheumatoid disease with a prevalence of 0.5 – 
1%, exceeded only by osteoarthritis. During the last decades treatment of RA and other 
autoimmune diseases has been revolutionised with the introduction of biological treatments. 
Even though this has greatly improved our ability to manage disease progress there are still 
non-responders and immunosuppression itself is associated with severe side effects such as 
infections and malignancies. An intriguing future treatment would be to re-establish the self-
tolerance once broken. This would treat the cause of the disease and potentially cure it.  
 
One of the recognised self-antigens in RA is collagen type II (CII). CII makes up 85-90% of 
the collagen content of articular cartilage and is expressed exclusively in joints and the 
vitreous humour. In this study we use collagen-induced arthritis (CIA), which is a well-
established mouse model of RA. CIA was first described by Trentham et al (1) in 1977. 
Typically mice are immunised through injection of a CII and complete Freund’s adjuvant and 
boosted with an injection of collagen type II and incomplete Freund’s adjuvant 3-5 weeks 
later. Clinical symptoms of arthritis can be observed within 4 to 5 weeks after immunisation. 
Histologically, inflamed joints of CIA and RA resemble one another, with synovial immune 
cell infiltration, cartilage destruction and bone erosion (2). The aetiology of RA is not fully 
understood, but certain MHC II haplotypes is highly associated with disease susceptibility. 
These haplotypes share certain sequences in the protein binding pocket (3) suggesting a 
common required affinity. Likewise CIA pathogenesis require certain MHC II H-2 complex 
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haplotypes with high affinity for CII. Serologically rheumatoid factor, anti-citrullinated 
protein antibodies and anti-CII antibodies have been observed in both conditions. In humans, 
anti-CII antibodies seems to be present particularly at onset of RA (4, 5) and are associated 
with a good prognosis (6). 
 
It has long been known that tolerance can be induced in mice by prophylactic treatment with 
soluble CII under non-inflammatory conditions (7-9). The immunodominant T cell epitope of 
CII in both RA and CIA is amino acids 259-270 (10-16). To further investigate the 
importance of different types of antigen presenting cells (APCs) in development and 
maintenance of CIA, Inger Gjertsson et al (17) published a report using lentiviral based gene 
therapy as a way to increase endogenous loading of this CII epitope on MHC II in mice. The 
advantages of this approach is that it 1) allows prolonged expression of the CII epitope (aa 
259-270) on APCs, 2) specific APCs e.g. B cells can be targeted and 3) the epitope expression 
is endogenous and dos not activate the APC. 
 
An efficient way to force expression of a peptide on MHC II is to insert it in invariant chain 
(18). This approach was used used to construct a lentiviral vector where the expression of the 
CII T cell epitope (aa 259-270) was forced on MHC II by exchanging the original class II-
associated invariant chain peptide (CLIP) sequence for the CII aa 259-270 sequence (LNT-
CII vector). Normally, the invariant chain is cleaved and dissociated from the MHC II 
complex in the acidic environment of the endosome (figure 1). CLIP occupies the protein 
binding grove in MHC II remains bound to prevent binding of endogenous peptides. Through 
interactions with HLA-DM, CLIP is eventually dissociated and a phagocytised antigen is 
loaded on MHC II and presented to T cells on the cell surface (19). Mice susceptible to CIA 
carry the H2q-haplotype, which have a high affinity to CII epitope (aa 259-270). Using our 
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vector, this leads to inability of the CII epitope to dissociate from MHC II during loading 
process (figure 1). In turn, this leads to abnormally high loading of the collagen type II 
epitope on MHC II on all antigen presenting cells.  
 
 
Original gene: 
 
LNT-CII vector: 
 
 
Figure 1. These pictures illustrate the normal (top picture) role of invariant chain and CLIP from synthesis 
of MHC II to antigen loading as well as the way our lentiviral vector leads to loading of CII epitope on MHC 
II (bottom picture). See main text for more detailed description. 
Adapted from original picture in Immunobiology, 6/e (Garland Science 2005). 
MHC class II Invariant chain CII epitopeCLIP HLA-DM Phagocytised antigen
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Since that first report, our group has performed several studies, all but one unpublished at 
present (20), where haematopoietic stem cells are harvested from donor mice and transduced 
in vitro with lentiviral particles (figure 2). Recipient mice are lethally irradiated and 
transplanted with transduced haematopoietic stem cells. In a previous unpublished study this 
treatment induced substantial antigen-specific tolerance in LNT-CII animals. Only 5% of 
them developed arthritis whereas 95% of LNT-CLIP animals did (figure 3). How the 
tolerance is mediated is not fully understood. In this previous study a 96 gene quantitative 
PCR array of mRNA of inflammatory genes was carried out at day 14 and day 28 after CIA 
induction. Results were inconclusive. To investigate the immunological events during the 
early phase after immunisation we now perform the 96 gene quantitative PCR array at day 0, 
day 3 and day 5 after CIA induction, with the aim to identify potential mediators of tolerance 
that could provide novel targets for tolerance induction in human RA. 
 
Figure 2. Schematic diagram of the transplantation procedure for LNT-CII mice. 
Lentiviral vectorsCII epitope
Donor Hematopoetic stem cells
Recipient Irradiation Recipient Repopulation Immunisation
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Interferon gamma and Th1/Th17 cells in arthritis 
 
Interferon gamma (IFN-ɣ) is considered a pro-inflammatory cytokine and is the hallmark of 
TH1 cells. The main objective for TH1 cells is to combat intracellular bacteria and viruses. 
Activation of the IFN-ɣ receptor leads to JAK/STAT pathway signalling through 
phosphorylation of STAT1 (21). Together with IL-12, IFN-ɣ stimulates naïve CD4+ cells to 
T-bet expression and TH1 differentiation. IFN-ɣ is produced mainly by TH1 as well as natural 
killer cells and activates macrophages and stimulate IL-12 secretion by dendritic cells in a 
positive feedback loop.  
 
Historically the view of T helper cells has been based on the concept of the dichotomy of the 
TH1 and TH2 cells. TH1 cells were believed to be responsible for the tissue damage seen in 
 
Figure 3. Graph from a previous trial (unpublished). The Y-axis indicates score for clinical signs of 
arthritis and the x-axis indicates days after CIA induction. In the study from which the graph is taken 
5% of LNT-CII mice developed arthrithis whereas 95% of LNT-CLIP mice did. 
8 
 
infectious as well as autoimmune inflammation. With the description of the novel TH17 subset, 
this perception has been reviewed during the last decade. Though TH1 is still believed 
instrumental in initiation of autoimmune arthritis, focus has shifted towards TH17 for 
maintaining inflammation and progressive tissue damage (22-25). 
 
The exact role of IFN-ɣ in arthritis pathogenesis is not conclusively determined. Recent 
research have indicated a protective role in established RA and CIA by favouring TH1 
development over TH17 (26, 27).  
 
T regulatory cells and IL-10 
 
T regegulatory cells (Treg) are characterised by the expression of the transcription factor 
FoxP3, surface molecule CD25 (IL-2 receptor), co-inhibitory molecule CTLA-4 and secretion 
of anti-inflammatory IL-10. Treg induction takes place in the thymus and in peripheral 
lymphoid tissue. Tregs can inhibit inflammatory responses by secretion of anti-inflammatory 
cytokines e.g. IL-10 and IL-35 and membrane-bound TGF-β as well as direct cell-to-cell 
interactions. The latter seems to have the stronger suppressive effect (28). Stimulation of the 
IL-10 receptor gives rise to increased intracellular levels of phosphorylated STAT1 and 
STAT3. 
 
SOCS1 and the JAK/STAT pathway 
 
The supressor of cytokine signalling (SOCS) family of proteins, reviewed by multiple authors 
(29-31), are induced by various cytokine signalling and have a regulatory function through 
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negative feedback on the JAK/STAT pathway (figure 
4). As with other intracellular signalling pathways, our 
understanding of the complex mechanics of the 
JAK/STAT pathway is likely crude at best. Cytokines 
of paradoxical effects can signal through 
phosphorylation of the same STAT and the different 
cellular responses to this signalling are likely modified 
by other parallel signalling pathways. 
 
SOCS1 exerts its negative feedback by 
dephosphorylation of JAKs as well as targeting them 
for degradation by the proteasome (figure 5) (2, 32, 33). 
SOCS1 are induced by cytokines signalling through 
STAT1, STAT3 and STAT6 and can bind to all JAKs 
(34), though seemingly favouring STAT1 inhibition, 
the net result of SOCS1 activation favouring IFN-ɣ 
suppression (2, 30, 31).  
 
SOCS1 and Tregs have a paradoxical relationship. 
Though SOCS1 can inhibit Treg expansion through 
inhibition of cytokine signalling, such as the IL-2 loop, 
it has also been shown that SOCS1 is essential for the regulatory phenotype of FoxP3+ cells. 
SOCS1 deficient mice have a larger compartment of FoxP3+ cells, though these lack 
regulatory cytokine secretion and instead produce IL-17 and IFN-ɣ. FoxP3 downregulates 
 
Figure 4. Schematic diagram 
showing the principals behind 
JAK/STAT pathway signalling. A 
cytokine binding its receptor leads 
to conformation changes in the 
receptors intracellular domain. 
These, in turn, allows JAKs to bind. 
JAKs phosphorylates the receptor 
allowing for STATs to bind the 
receptor, leading to 
phosphorylation of the STATs. 
Phosphorylated STATs dissociates 
from the receptor, dimerises and 
relocate to the nucleus to act as 
transcription factors. Induced 
transcription typically result in 
increased cytokine production, 
receptor upregulation and 
negative feedback through the 
SOCS family of proteins. 
Image adapted from Wikipedia 
(http://en.wikipedia.org/wiki/File:
Formalization-of-Jak-Stat-
Pathway.png). 
SOCS
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SOCS1, which might be important to allow for the positive feedback loop of IL-2 secretion, 
needed for Treg expansion (30, 35, 36). 
 
Both IL-10 and IL-6 induce STAT3 
phosphorylation and have the ability to induce 
SOCS1. In a previous study by our group, using 
a vector for inflammation dependent locally 
increased IL-10 production we showed 
significantly decreased serum levels of IL-6 and 
an increase in Socs1 mRNA (20). Dysregulation 
of the SOCS feedback system can have 
importance for maintaining manifest 
autoimmune disease. For instance, Yamana et al 
show that under chronic inflammation with prolonged elevated IL-6 levels and high  SOCS1 
expression, IL-10’s ability to effect CD4+ T cells is greatly decreased and substantially higher 
concentrations of IL-10 is needed to augment STAT3 phosphorylation. This could shown in 
human RA patients with active disease, both compared to healthy controls and RA patients 
with inactive disease (33). 
  
 
Figure 5. Schematic diagram illustrating 
principal induction and effects of SOCS1. 
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AIM AND SPECIFIC OBJECTIVES 
 
The aim of this study was to generate new hypothesises regarding early mediation of the 
tolerance underlying tolerance in CIA. 
 
This will be performed by determining the mRNA expression of 96 inflammatory genes and 
protein expression of selected genes at days 0, 3 and 5 after CIA induction. 
 
ETHICS 
 
All experiments were approved by the local ethics committee. 
 
 
  
12 
 
MATERIALS AND METHODS 
 
Male DBA/1 mice that had previously undergone gene therapy with haematopoietic stem cells 
transduced with LNT-CII/LNTCLIP were used (n=20). In brief, mice had been lethally 
irradiated and transplanted with LNT-CII/LNT-CLIP lentiviral particles (17, 37, 38). Mice 
were sacrificed before CIA induction (day 0) and three days after (day 3) or five days after 
(day 5) CIA induction. CIA was induced by subcutaneous injection with rat CII (1 mg/ml) 
and complete Freund’s adjuvant in a total volume of 100 µl.  
 
At termination blood, spleen and draining lymph nodes were obtained. Blood samples were 
collected in Eppendorf tubes with 40 µl Heparin LEO 5000 IU/ml (LEO Pharma, Imported by 
Oripharm). Plasma was stored at -20°C. Spleens were collected to previously weighed Falcon 
tubes containing PBS. Tubes were weighed again to determine the weight of the spleens. A 
piece of the spleens was taken, embedded in OCT and frozen in isopentane and dry ice for 
subsequent immunohistochemistry. Another piece of the spleens was frozen immediately in a 
2 ml Safe seal tube for PCR preparation. The remaining spleen was prepared as a single cell 
suspension for FACS analysis. One lymph node was removed to a previously weighed Safe 
seal tube and frozen on dry ice. The tube and lymph node was weighed again before being 
prepared for PCR. Several lymph nodes per mouse were prepared as a single cell suspension 
for FACS analysis. One lymph node per mouse was taken, embedded in OCT and frozen in 
isopentane and dry ice for immunohistochemistry. 
 
Quantitative PCR 
 
mRNA was prepared from lymph nodes taken day 0, day 3 and day 5 using RNEasy Mini Kit 
and QIAcube (QIAGEN) with protocol RNeasy Mini Kit Cells and Tissue with DNase Digest 
according to the manufacturers instruction, with the exception of using 30 µl elution volume 
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instead of 50 µl. RNA concentration was measured using a ND-1000 Spectrophotometer 
(NanoDrop). cDNA synthesis was made using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems) including RNase inhibitor in a Veriti 96 Well Thermal Cycler 
(Applied Biosystems). cDNA was run in the 384-well microfluid card Taqman Array Mouse 
Immune Panel (Applied Biosystems/Life Technologies) detecting 90 + 6 genes using a ViiA 7 
Real-Time PCR System (Applied Biosystems/Life Technologies). β-actin (Actb) and GADPH 
(Gadph) were selected as housekeeping genes. In a previous study, qPCR had been performed 
using the same Taqman Array on draining lymph nodes from day 14 and day 28. Relative 
quantification (RQ) was calculated from the sample from a naïve DBA/1 mouse. A separate 
qPCR was run in a regular 96 well plate for transcription factors Bcl6, Foxp3, Gata3, Rorc 
and Tbx21 using a ViiA 7 Real-Time PCR System (Applied Biosystems/Life Technologies). 
For this qPCR β-actin was used as a housekeeping gene. RQ was calculated from the same 
sample from a naïve DBA/1 mouse  
 
FACS 
 
Spleen and draining lymph node samples were pressed through a 70 µm cell strainer filter. 
The filter was washed with 10 ml FACS buffer. Cells were pelleted at 300 g for 10 min at 4°C 
and then resuspended in 0,5 ml FACS buffer. Cells were counted in a NucleoCounter NC-100 
(ChemoMetec A/S). Cell concentration was adjusted to 108 cells/ml. 50 µl cell suspension 
was removed to an Eppendorf tube for cell proliferations. The cells were further stained with 
Fc-block and the following antibodies CD4 (EF450), CD8 (PE-Cy7), CD25 (FITC), CD44 
(APC-H7), CD62L (PerCP) and ICOS (APC) and incubated in dark fridge for 20 minutes 
before being washed. Cells were then fixed, permeabilized and stained intracellulary for 
FoxP3 (PE). Florochromes minus ones (FMOs) were prepared for FITC, APC-H7, PerCp, 
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APC and PE. Cells were detected using FACSCanto II (BD sciences) and analysis was made 
using FlowJo Software (Tree Star Inc.). 
 
Cell proliferations 
 
Cell proliferations were performed using spleens obtained from mice taken at day 5 after CIA 
induction. Both unstimulated proliferation and CII-proliferation were done. Supernatants were 
frozen at -20°C. Proliferation was determined as IFN-ɣ production. ELISA for IFN-ɣ was 
performed using Mouse IFN-gamma DuoSet (R&D Systems, Cat: DY485) according to the 
manufacturer’s instructions. Triplets of supernatant of both stimulated and unstimulated 
proliferations were used. The plates were analysed using a SpectraMax 340PC384 
Absorbance Microplate Reader (Molecular Devices) and SoftMax Pro 5.2 Microplate Data 
Acquisition & Analysis Software (Molecular Devices). 
 
Cytometric bead array 
 
Blood plasma from days 0, 3 and 5 was used. The plasma had been stored in -20°C. 
Circulating levels of cytokines were assessed using cytometric bead array (CBA). The Mouse 
Th1/Th2/Th17 Cytokine Kit (BD, Cat: 560485) was used. The kit detects IL-2, IL-4, IL-6, IL-
10, IL-17A, TNF-α and IFN-ɣ. The kit was used following the manufacturer’s instructions. 
Samples were acquired using BD FACSVerse (BD Biosciences). The samples was analysed 
using FCAP Array v3.0 (Soft Flow, Inc., R&D). 
 
Immunohistochemistry 
 
Immunohistochemical staining with Foxp3, SOCS1 and SOCS3 antibodies was planned. 
Frozen 6 µm sections of one spleen from a previous study was used for optimization of the 
staining protocol. Sections were fixated with acetone. ImmPress kits from Vector 
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Laboratories was used for protein blocking. Primary antibody was applied and the sections 
were left to incubate in a humidity chamber in 2–8°C over night. Endogenous peroxidases 
were quenched using PBS supplimented with 0.3% H2O2 and 0.1% saponin. Protein block, 
serum free (Dako Sweden AB, cat: X0909) was used for a second protein block before 
applying secondary antibody from ImmPress kits. Secondary antibody was allowed to 
incubate in room temperature for >30 min. ImmPACT AEC Peroxidase (HRP) Substrate 
(Vector Laboratories Inc, cat: SK-4205) was used as staining reagent. Sections were then 
stained with Mayer’s hematoxilin before mounting with VectaMount AQ Aqueous Mounting 
Medium (Vector Laboratories Inc, cat: H-5501).  
 
A range of dilutions were tested for each primary antibody. SOCS1 and SOCS3 primary 
antibodies were tested in the following dilutions 1:50, 1:100, 1:200, 1:400, 1:800 and 1:1600. 
Foxp3 primary antibody was tested in the following dilutions 1:50, 1:100, 1:200 and 1:400. 
Optimal concentrations are listed in table 1. Negative controls for each secondary antibody 
were used. During primary antibody incubation these negative control incubated with only 
antibody dilution buffer (PBS supplemented with 0.1% saponin and 0.5% BSA). See table 1 
for specific materials and concentrations. 
 
Protein Primary antibody Original 
concentration 
Optimal 
concentration 
Optimal 
dilution 
Secondary antibody and first 
protein block 
Optimal 
substrate 
reaction 
time 
Foxp3 Anti-Mouse/Rat Foxp3 
Purified clone FJK-16s 
(eBioscience, cat: 14-
5773-82).  
0.5 mg/ml 2.5 µg/ml 1:200 ImmPRESS HRP Anti-Rat Ig 
(Peroxidase) Polymer 
Detection Kit (Vector 
Laboratories Inc, cat: MP-7404) 
30 min 
SOCS1 Rabbit Anti-SOCS1 
Polyclonal Antibody 
(Bioss Antibodies, cat: 
bs-0113R).  
1 mg/ml 1.25 µg/ml 1:800 ImmPRESS HRP Anti-Rabbit Ig 
(Peroxidase) Polymer 
Detection Kit (Vector 
Laboratories Inc, cat: MP-7401) 
20 min 
SOCS3 Rabbit Anti-SOCS3 
Polyclonal Antibody 
(Bioss Antibodies, cat: 
bs-0580R) 
1 mg/ml 1.25 µg/ml 1:800 ImmPRESS HRP Anti-Rabbit Ig 
(Peroxidase) Polymer 
Detection Kit (Vector 
Laboratories Inc, cat: MP-7401) 
10 min 
Table 1. Detailing materials for immunohistochemistry and optimal concentrations and reaction times for 
these. 
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Statistical analysis 
 
To evaluate the PCR-data and to generate a hypothesis, RQ values from the mRNA qPCR 
arrays was first investigated in multivariate factor analysis using the software SIMCA (version 
13.0.3.0, Umetrics). Principal component analysis (PCA) was used to evaluate the general 
spread of the data. Further, Orthogonal projections to latent structures-discriminant analysis 
(OPLS-DA) and Partial least square regression (PLS) was used. OPLS-DA is a discriminant 
analysis and was used to investigate how gene expression differed between the groups at each 
time point. Variable importance for the projection (VIP) is a value describing the impact that each 
variable has on the total variance in the model. At each day, variables with a VIP >1 were noted 
for their association to either group. The pattern of association over time was then investigated. 
We limited the investigation to variables with consistent association to either of the groups. 
Variables with consistent association were further scrutinised; existing literature was consulted for 
relevancy, the data was checked for outliers and PLS analysis performed. A PLS analysis 
describes how the variations of one variable correlate with those of the other variables in the 
selected material. The aim of these statistical analyses was to single out potential candidates for 
further study.  
 
Univariate analyses were performed using Prism (GraphPad). 
 
Student’s involvement  
 
The mice were already transplanted at the start of the experiment. I observed when Pernilla 
Jirholt performed plasmid culturing and viral transduction. mRNA isolation, cDNA synthesis 
and qPCR were performed by Pernilla Jirholt with the me as an observer. I performed the 
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process on dummy samples. Statistical analysis of qPCR was performed by me. FACS was 
performed by Berglind Bergmann and FlowJo analysis by me. Cell proliferations was 
performed by Pernilla Jirholt. ELISA, CBA and immunohistochemistry was performed by me 
under the supervision of Sofia Andersson. 
 
  
18 
 
RESULTS 
  
Quantitative PCR 
 
In previous studies we have observed an 
evident difference in clinical signs and 
histologic evaluation of arthritis in LNT-CII 
mice compared to LNT-CLIP mice. To 
investigate possible explanations to these 
observations in the first days after immunisation we performed the qPCR array at days 0, 3 
and 5. Data from mice at day 14 and day 28, gathered in previous studies, was included. Table 
2 lists the number of mice with successful mRNA preparation that the qPCR assay could be 
performed on. The data for day 5 were heavily skewed and riddled with outliers. For that 
reason day 5 was excluded from the multivariate analyses.  
 
Table 3 lists the genes with consistent association to either group. After reviewing the data 
and existing literature our three main candidates for further study was Socs1, Hmox1 and 
Il12a. Hmox1 encodes the protein heme oxygenase 1 (HO-1) which catabolizes heme to 
biliverdin. Inhibition of HO-1 has been shown to decrease joint inflammation and cartilage 
destruction as well as inflammatory cytokine levels in CIA (39). Il12a encodes a subunit of 
both IL-12 and recently described anti-inflammatory cytokine IL-35 (40).  
 LNT-Ii-CLIP (n) LNT-Ii-CII (n) 
Day 0 2 2 
Day 3 3 2 
Day 5 3 3 
Day 14 4 4 
Day 28 3 5 
Table 2. Number of mice that the qPCR array 
was performed on. 
 
 
 
Table 3. List of genes with consistent association to the LNT-CII or LNT-CLIP group. A dot means positive association 
LNT-CII Hprt1 Socs1 Il12a Ccl3 Il15 Edn1 Col4a5 Cd28 Ccl2 Ccl19 Tnfrsf18Tfrc H2-Ea Ptgs2 Il7 Cxcr3
Day 0 • • • • • • • • • • • •
Day 3 • • • • •
Day 14 • • • • • • •
Day 28 • • • • • • • • • • •
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We decided to focus on Socs1. This decision was based on the limited frames of this report, 
the amount and quality of existing research and the strength of the findings in our data. 
 
According to the OPLS-DA analysis (i.e. the analysis that sorts the data according to its 
association to either LNT-CII or LNT-CLIP) at day 3,we found that Socs1 was the gene 
strongest associated with the tolerant LNT-CII group along with Il10 (figure 6A). According 
to the PLS analysis of Socs1 (i.e. how parameters co-variate with Socs1 expression) at day 3, 
its expression has a positive association with Il10, at the same time as it is negatively 
associated with expression of Ifng and Il6 (figure 6B). In figure 7 the expression of Ifng, Il6, 
Il10 and Socs1 are plotted over time. In the LNT-CII mice changes in expression of Il10 and 
Socs1 follows the same pattern while Ifng follows an inverted pattern. This is particularly 
marked at day 3 where expression levels of these three genes are the most separated. 
 
No significant differences could be seen in the separate qPCR for transcription factors Bcl6, 
Foxp3, Gata3, Rorc and Tbx21 (data not shown).  
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Figure 6. A) Columns loading plot of OPLS-DA on day 3. This is a discriminant analysis and mice are 
assigned to groups. A bar above the axis indicates higher expression in the LNT-CII group and a bar 
below the axis indicates higher expression in the LNT-CLIP group. The bars marked in blue represent 
the respective groups. Bars for Socs1, Il10, Il6 and Ifng are marked with red. Socs1 and Il10 are the 
genes with the strongest association to the LNT-CII group. Second to Bcl2l1, Ifng is the gene strongest 
associated to the LNT-CLIP group. Il6 is predominantly associated with LNT-CLIP. 
B) Columns loading plot of PLS analysis on Socs1 on day 3. In this analysis mice are not assigned to 
groups. Both LNT-CLIP and LNT-CII mice taken at day 3 are included. A bar above the axis indicates that 
expression of the gene covariates in a positive way with Socs1 and a bar below the axis indicates that 
expression of the gene covariates in a negative way with Socs1. Bars for Socs1, Il10, Il6 and Ifng are 
marked with red. The graph illustrates that expression of Socs1 have a strong positive association to the 
expression of Il10 and a strong negative association to the expression of Ifng and Il6. 
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Figure 7. Ifng, Il6, Il10 and Socs1 plotted over time. At day 3 the most evident separation between the 
groups can be observed. In the LNT-CII mice both Il10 and Socs1 are upregulated at day 3, while Ifng is 
downregulated. Due to mass significance statistical calculations cannot be performed. It can be noted that 
over time, the levels of Il10 expression and Socs1 expression in the LNT-CII mice seems to share the same 
pattern, while expression of Ifng exhibits the inverted pattern. 
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FACS 
 
To investigate T cell subsets FACS was performed on spleen and draining lymph nodes at day 
0, day 3 and day 5. The frequency of regulatory T cells, defined as CD4+FoxP3+ cells, is 
significantly increased at day 3 in both draining lymph nodes and spleen of LNT-CII mice 
(figure 8A and B).  
 
At day 5 the proportion of CD4+FoxP3+ cells were normalised in draining lymph nodes. In 
the spleen there was a significantly decreased frequency of CD4+Foxp3+ cells in LNT-CII 
mice. This suggests that events crucial to tolerance takes place very early after induction of 
arthritis.   
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Figure 8. A) CD4+FoxP3+ cells in draining lymph nodes. Unpaired parametric T test calculated using Prism showed a 
significantly higher frequency in LNT-CII mice, p=0.0302 (CI=0.04753 to 5.591) at day 3. B) CD4+FoxP3+ cells in spleen. 
Unpaired parametric T test calculated using Prism showed a significantly higher frequency in LNT-CII mice, p=0.0060 
(CI=1.687 to 5.380) at day3. On day five the frequency was significantly lower in the tolerant mice, p=0.0141 (CI=0.3204 to 
1.930). C) Representative gating chart. 
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ELISA 
 
The results from the ELISA was inconclusive as all samples was negative (data not shown). 
We suspect that proliferations failed and the cells were dead. The standard curve obtained had 
a R2 value of 1.  
 
Cytometric bead array 
 
Results were inconclusive. Results for TNF were not available as the standard curve for had a 
R2 value <98% why the software wouldn’t fit them. All other standard curves had a R2 value 
>98%. Results for IL-2, IL-4, IL-10 and IFN-ɣ were all, or to an extent not allowing 
comparison between groups, below standard range. Concentrations detected of IL-17A and 
IL-6 contained no significant difference between the groups. Results shown in table 4. 
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Results 
File 
Il-
10 
Message 
IL-
17A 
Message TNF Message 
IFN-
γ  
Message IL-6 Message IL-4 Message IL-2 Message 
R1 0,00 II 1,92   N/A   0,65   1,79   0,00 II 2,58 I 
R2 0,00 II 1,36   N/A   0,00 II 0,46   0,00 II 0,00 II 
R3 0,00 II 1,12   N/A   0,00 II 3,43   0,00 I 2,00 I 
R4 0,00 II 2,05   N/A   0,00 II 2,41   0,00 II 1,41 I 
R5 0,00 II 1,50   N/A   0,47   2,47   0,00 II 3,37   
R6 0,00 II 0,24   N/A   0,00 II 4,74   0,00 II 0,00 II 
R7 0,00 II 1,50   N/A   0,47   4,08   0,00 II 1,12 I 
R8 0,00 II 1,12   N/A   0,96   0,04   0,00 II 1,83 I 
R9 0,00 II 1,50   N/A   1,03   3,49   0,00 I 0,00 II 
R10 0,00 II 0,70   N/A   0,47   2,47   0,00 II 1,41 I 
Q1 0,00 II 1,96   N/A   0,09 I 0,00   0,00 I 0,00 II 
Q2 0,00 II 3,18   N/A   0,32   2,60   0,00 I 1,12 I 
Q3 0,00 II 1,17   N/A   0,00 II 0,00 I 0,00 II 0,00 II 
Q4 0,00 II 1,36   N/A   0,37   3,43   0,00 II 2,16 I 
Q5 0,00 II 1,12   N/A   0,19 I 10,47   0,00 II 0,00 II 
Q6 0,00 II 0,87   N/A   0,00 II 0,52   0,00 II 0,00 II 
Q7 0,00 II 0,59   N/A   0,77   2,10   0,00 I 0,00 II 
Q8 0,00 II 1,69   N/A   0,77   4,81   0,00 II 1,12 I 
Q9 0,00 II 1,07   N/A   0,00 II 0,70   0,00 II 1,41 I 
Q10 0,00 II 1,45   N/A   0,00 II 0,10   0,00 II 1,83 I 
Table 4.  
Results from CBA. 
LNT-CLIP: R1-3 = d0, R4-6 = d3, R7-10 = d5 
LNT-CII: Q1-3 = d0, Q4-6 = d3, Q7-10 = d5 
Concentrations in pg/ml.  
Message: I: Fitting: Below standard range II: Below standard range and out of invertable range 
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DISCUSSION 
 
This report creates new hypothesises with respect to the underlying immunological 
mechanisms in antigen-specific tolerance in CIA. We show that tolerant LNT-CII mice up- 
regulates the Socs1 gene at day 3 after CIA induction. Similarly, the Il10 gene is up-regulated 
while Infg is down-regulated at the same point. The PLS analysis on all mice taken day 3 
suggests that expression of Socs1 have a positive correlation expression of Il10 and negative 
association with genes for pro-inflammatory cytokines IFN-ɣ and IL-6. Due to mass 
significance and small number of observations statistical tests cannot be performed, but we 
would argue that this pattern strengthens the case against this being merely coincidental. 
Further support can be found in the seemingly interdependent pattern of Socs1, Il10 and Ifng 
when plotted over time (figure 8). We have found a significant increase in CD4+FoxP3+ T 
regulatory cells in tolerant LNT-CII mice at day 3, which could explain an increased Il10 
expression. The CD4+CD44+Foxp3+ population is known for high IL-10 secretion. There 
was a tendency towards simultaneous increase in this population in the LNT-CII mice, though 
none significant (data not shown). IL-10 is known to be able to induce Socs1 and in our 
group’s previous study (20) with local inflammation dependent overexpression of IL-10 we 
found an increased Socs1 expression in draining lymph nodes and reduced IL-6 serum levels, 
which supports the findings of this study. There are many reports supporting a protective role 
of IFN-ɣ in established RA. However, this does not necessarily contradict our findings as they 
generally describe established disease. Studies of early RA are scarce due to the intrinsic 
delay of diagnosis from onset of disease. IFN-ɣ has been reported to mediate pharmacological 
inhibition of CIA (26, 41). Further study is needed to fully evaluate the impact of the 
temporary early suppression of IFN-ɣ seen in this study.  
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Our hypothesis is that the process leading to the tolerance is initiated even before 
immunisation. We propose that immediate differences in the inflammatory response to 
immunisation diverts the LNT-CII animals down a tolerant path. We believe that a part of this 
process is illustrated by our observations at day 3: Expansion of the Treg compartment with 
increased IL-10 expression in the LNT-CII mice induces increased expression of SOCS1. 
SOCS1 in turn exerts a general negative feedback on the JAK/STAT pathway, decreasing 
signalling by and mRNA expression of pro-inflammatory cytokines such as INF-g and IL-6. 
How big a part this is of the whole picture cannot be concluded within the frame of this study. 
 
Protein expression of IL-16, IL-10, IFN- ɣ and SOCS1 
 
To verify the mRNA expression of chosen genes on a protein level, several methods were 
used. To detect IFN-ɣ, we performed an ELISA on supernatants from the proliferation 
experiment. However, no detectable levels of cytokines were found. This could be due to 
multiple reasons: 1) The proliferations failed and the cells were dead, 2) our detection 
threshold was too high and that a lower standard curve might have been more suitable.  
 
To detect various cytokines in plasma we performed a CBA anylisis. Unfortunately we could 
not detect any cytokines. Some possibilities as to why might be: 1) Many of the cytokines 
measured, such as IL-2 and IL-10, is primarily believed to have parachrine functions and does 
not likely reach detectable concentrations in serum even during high secretion, 2) the plasma 
had been frozen which may have influenced the protein configuration and thus antibody 
binding sites, 3) the CBA might not be sensitive  
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To detect SOCS1, 3 and Foxp3 in draining lymph nodes by immunohistochemistry, we titred 
all adequate antibodies. However, due to lack of time this part of the project was not 
completed, but will be carried out in the future. 
 
Strengths and weaknesses 
 
The main weakness of this work is the small number of observations and mass significance in 
a 96 gene array. The low quality of data from qPCR performed from day 5 lead to exclution 
of this time point, which was a loss. The failure to verify mRNA data on a protein level is an 
apparent weakness.  
 
Future applications 
 
Re-establishment of tolerance in autoimmune diseases would be the ultimate treatment. To 
achieve that, we need to understand the underlying immunological mechanisms in greater 
detail. Gene therapy can be on option for inborn diseases such as severe immunodeficiencies 
but presently not for autoimmune conditions. However, research like ours leads to a deeper 
understanding of the disease pathogenesis. This improves the characterisation of the 
individual patient’s pathogenesis and help the physician to personalise the pharmacologic 
treatment. Research like ours also reveal new immunological events that can provide novel 
treatment targets. An example closely related to this report is the recent introduction of JAK 
inhibitors the treatment of RA. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Med immunologisk tolerans menar man immunsystemets förmåga att tåla sig den egna 
kroppen, men samtidigt reagera kraftfullt på liknande komponenter från främmande 
organismer. Trots en mängd säkerhetssystem, kan denna tolerans brytas och en immunitet mot 
kroppens egna beståndsdelar utvecklas. Det är denna förmåga till immunitet som utnyttjas när 
vi vaccinerar oss. Immunitet mot sig själv benämns som autoimmunitet. 
Ledgångsreumatism kallas medicinskt reumatoid artrit (RA). Artrit betyder just 
ledinflammation. RA är en vanlig autoimmun sjukdom som drabbar upp till 1% av 
västerländska befolkningar. Obehandlad kan sjukdomen leda till mycket handikappande 
ledförstörelse. Man kan inte bota den här typen av sjukdomar, utan behandling av RA inriktar 
sig på att dämpa immunsystemet. Trots att vår förmåga att hindra sjukdomens förlopp har 
ökad dramatiskt de senaste decennierna medför sådan behandling alltid en nedtryckning av 
immunsystemets gynnsamma funktioner. Man blir alltså känsligare för och riskerar allvarliga 
infektioner. Den ultimata behandlingen vore att återskapa toleransen och därmed bota 
sjukdomen. 
Vi använder en sjukdom hos möss som liknar RA, en så kallad musmodell för RA, för att 
studera sjukdomens mekanismer. Den musmodell vi anväder kallas collageninducerad artrit 
(CIA) och bygger på att möss immuniseras mot komponenter i ledbrosket. De får då en 
sjukdom som liknar RA. 
Vi har utvecklat ett system för att med hjälp av skräddarsydda virus introducera en ny gen i 
mössens immunceller. De som får denna gen utvecklar inte sjukdomen trots att de 
immuniseras på samma sätt. Vi använder den här modellen för att studera mekanismerna 
bakom tolerans i hopp om att hitta nya sätt att behandla RA. 
Nu har vi för första gången studerat de första dagarna efter immunisering för att försöka hitta 
tidiga mekanismer som förhindrar sjukdomsutveckling. Vi har tittat på vilka typer av 
immunceller som finns samt hur mycket aktivitet de har i ca 90 gener relaterade till 
inflammation. 
Vi såg att en inflammationsdämpande typ av cell kallad regulatorisk T-cell var vanligare hos 
de toleranta mössen tre dagar efter immunisering. Vid samma tidpunkt var gener för 
antiinflammatoriska ämnen uppreglerade i dessa möss samtidigt som gener för 
proinflammatoriska ämnen var nedreglerade. Vi har också identifierat ett protein kallat 
SOCS1 som vi tror kan spela en viktig roll i att skapa den här skillnaden. 
Virusbaserade metoder såsom denna är ännu inte lämplig att använda på människor på bred 
front. Dessutom ger vår metod störst effekt om den utförs före sjukdomsutveckling. Däremot 
kan forskning, liksom vår, leda till ökad förståelse för vilka som får sjukdomen och varför. 
Den kan också leda till att vi bättre förstår vilken patient som kommer att svara på vilket utav 
våra många nya läkemedel. En mer skräddarsydd behandling skulle kunna leda till bättre 
resultat med mindre biverkningar.  
  
31 
 
REFERENCES 
 
1. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental 
model of arthritis. Journal of Experimental Medicine. 1977;146(3):857-68. 
2. Schurgers E, Billiau A, Matthys P. Collagen-induced arthritis as an animal model for 
rheumatoid arthritis: focus on interferon-gamma. Journal of interferon & cytokine research : the 
official journal of the International Society for Interferon and Cytokine Research. 2011;31(12):917-26. 
3. Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, et al. 
Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS genetics. 
2008;4(4):e1000024. 
4. Kim WU, Cho ML, Jung YO, Min SY, Park SW, Min DJ, et al. Type II collagen 
autoimmunity in rheumatoid arthritis. The American journal of the medical sciences. 
2004;327(4):202-11. 
5. Kim WU, Yoo WH, Park W, Kang YM, Kim SI, Park JH, et al. IgG antibodies to type II 
collagen reflect inflammatory activity in patients with rheumatoid arthritis. The Journal of 
rheumatology. 2000;27(3):575-81. 
6. Mullazehi M, Wick MC, Klareskog L, van Vollenhoven R, Ronnelid J. Anti-type II 
collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis. 
Arthritis research & therapy. 2012;14(3):R100. 
7. Hasselberg A, Schon K, Tarkowski A, Lycke N. Role of CTA1R7K-COL-DD as a novel 
therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis. Arthritis 
and rheumatism. 2009;60(6):1672-82. 
8. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ. Suppression of 
type II collagen-induced arthritis by intragastric administration of soluble type II collagen. 
Proceedings of the National Academy of Sciences of the United States of America. 1986;83(19):7443-
6. 
9. Honda A, Ametani A, Matsumoto T, Iwaya A, Kano H, Hachimura S, et al. Vaccination 
with an immunodominant peptide of bovine type II collagen induces an anti-TCR response, and 
modulates the onset and severity of collagen-induced arthritis. International immunology. 
2004;16(5):737-45. 
10. Rosloniec EF, Whittington KB, Zaller DM, Kang AH. HLA-DR1 (DRB1*0101) and DR4 
(DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from 
human type II collagen. Journal of immunology (Baltimore, Md : 1950). 2002;168(1):253-9. 
11. Andersson EC, Hansen BE, Jacobsen H, Madsen LS, Andersen CB, Engberg J, et al. 
Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in 
type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 
transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 
1998;95(13):7574-9. 
12. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-
DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity. 
1997;7(4):473-81. 
13. Diab BY, Lambert NC, L'Faqihi FE, Loubet-Lescoulie P, de Preval C, Coppin H. Human 
collagen II peptide 256-271 preferentially binds to HLA-DR molecules associated with susceptibility to 
rheumatoid arthritis. Immunogenetics. 1999;49(1):36-44. 
14. Kjellen P, Brunsberg U, Broddefalk J, Hansen B, Vestberg M, Ivarsson I, et al. The 
structural basis of MHC control of collagen-induced arthritis; binding of the immunodominant type II 
collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules. European journal of immunology. 
1998;28(2):755-67. 
15. Michaelsson E, Andersson M, Engstrom A, Holmdahl R. Identification of an 
immunodominant type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the 
level of determinant selection. European journal of immunology. 1992;22(7):1819-25. 
32 
 
16. Rosloniec EF, Whittington KB, Brand DD, Myers LK, Stuart JM. Identification of MHC 
class II and TCR binding residues in the type II collagen immunodominant determinant mediating 
collagen-induced arthritis. Cellular immunology. 1996;172(1):21-8. 
17. Gjertsson I, Laurie KL, Devitt J, Howe SJ, Thrasher AJ, Holmdahl R, et al. Tolerance 
induction using lentiviral gene delivery delays onset and severity of collagen II arthritis. Molecular 
therapy : the journal of the American Society of Gene Therapy. 2009;17(4):632-40. 
18. Koch N, van Driel IR, Gleeson PA. Hijacking a chaperone: manipulation of the MHC 
class II presentation pathway. Immunology today. 2000;21(11):546-50. 
19. Zarutskie JA, Busch R, Zavala-Ruiz Z, Rushe M, Mellins ED, Stern LJ. The kinetic basis of 
peptide exchange catalysis by HLA-DM. Proceedings of the National Academy of Sciences of the 
United States of America. 2001;98(22):12450-5. 
20. Henningsson L, Eneljung T, Jirholt P, Tengvall S, Lidberg U, van den Berg WB, et al. 
Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice. PloS one. 
2012;7(11):e49731. 
21. Boselli D, Ragimbeau J, Orlando L, Cappello P, Capello M, Ambrogio C, et al. Expression 
of IFNgammaR2 mutated in a dileucine internalization motif reinstates IFNgamma signaling and 
apoptosis in human T lymphocytes. Immunology letters. 2010;134(1):17-25. 
22. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 
hypothesis of T cell-mediated tissue damage. Nature medicine. 2007;13(2):139-45. 
23. Azizi G, Jadidi-Niaragh F, Mirshafiey A. Th17 Cells in Immunopathogenesis and 
treatment of rheumatoid arthritis. International journal of rheumatic diseases. 2013;16(3):243-53. 
24. van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, et al. Th17 
cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix 
metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including 
autocrine interleukin-17A production. Arthritis and rheumatism. 2011;63(1):73-83. 
25. Lubberts E. Th17 cytokines and arthritis. Seminars in immunopathology. 
2010;32(1):43-53. 
26. Pavlovic V, Dimic A, Milenkovic S, Krtinic D. Serum levels of IL-17, IL-4, and INFgamma 
in Serbian patients with early rheumatoid arthritis. Journal of research in medical sciences : the 
official journal of Isfahan University of Medical Sciences. 2014;19(1):18-22. 
27. Lee J, Lee J, Park MK, Lim MA, Park EM, Kim EK, et al. Interferon gamma suppresses 
collagen-induced arthritis by regulation of Th17 through the induction of indoleamine-2,3-
deoxygenase. PloS one. 2013;8(4):e60900. 
28. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal 
T cell activation in vitro by inhibiting interleukin 2 production. The Journal of experimental medicine. 
1998;188(2):287-96. 
29. Liang Y, Xu WD, Peng H, Pan HF, Ye DQ. SOCS signaling in autoimmune diseases: 
Molecular mechanisms and therapeutic implications. European journal of immunology. 2014. 
30. Larkin J, 3rd, Ahmed CM, Wilson TD, Johnson HM. Regulation of Interferon Gamma 
Signaling by Suppressors of Cytokine Signaling and Regulatory T Cells. Frontiers in immunology. 
2013;4:469. 
31. Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A. Suppressors of cytokine 
signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and 
SOCS3. Arteriosclerosis, thrombosis, and vascular biology. 2011;31(5):980-5. 
32. Adriaansen J, Vervoordeldonk MJ, Tak PP. Gene therapy as a therapeutic approach for 
the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology 
(Oxford, England). 2006;45(6):656-68. 
33. Yamana J, Yamamura M, Okamoto A, Aita T, Iwahashi M, Sunahori K, et al. Resistance 
to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 
1 in CD4+ T cells from patients with rheumatoid arthritis. Arthritis research & therapy. 
2004;6(6):R567-77. 
33 
 
34. Ilangumaran S, Rottapel R. Regulation of cytokine receptor signaling by SOCS1. 
Immunol Rev. 2003;192:196-211. 
35. Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-
146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010;142(6):914-29. 
36. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, et al. Foxp3-dependent 
microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 
2009;30(1):80-91. 
37. Eneljung T. Self-tolerance in collagen induced arthritis [Doctoral thesis]. GUPEA: 
University of Gothenburg. Sahlgrenska Academy; 2013. 
38. Eneljung T, Tengvall S, Jirholt P, Henningsson L, Holmdahl R, Gustafsson K, et al. 
Antigen-specific gene therapy after immunisation reduces the severity of collagen-induced arthritis. 
Clinical & developmental immunology. 2013;2013:345092. 
39. Devesa I, Ferrandiz ML, Terencio MC, Joosten LA, van den Berg WB, Alcaraz MJ. 
Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis. 
Arthritis and rheumatism. 2005;52(10):3230-8. 
40. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel 
cytokine with therapeutic effects against collagen-induced arthritis through the expansion of 
regulatory T cells and suppression of Th17 cells. European journal of immunology. 2007;37(11):3021-
9. 
41. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, et al. 4-1BB-mediated 
immunotherapy of rheumatoid arthritis. Nature medicine. 2004;10(10):1088-94. 
 
 
